12:00 AM
Aug 29, 2011
 |  BC Week In Review  |  Company News  |  Other News

Novartis, Novo Nordisk endocrine/metabolic news

Novartis' Sandoz Inc. unit filed a suit in the U.S. District Court for the Eastern District of Michigan seeking declaratory judgment that its ANDA submission for a generic version of Novo's diabetes drug Prandin repaglinide does not infringe U.S. Patent No. 6,677,358 and that the patent is...

Read the full 223 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >